TESARO is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in development and commercialization of some of their therapeutics.
“In testing conducted in mice, treatment of tumor cells with niraparib resulted in the prolonged inhibition of PARP. Niraparib treatment sensitized tumor cells to subsequent radiotherapy and chemotherapy in xenograft models.”
TESARO, Inc., incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. The Company is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. [Source: Reuters]
Company Website: http://www.tesarobio.com